相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP
Annette J. Vangsted et al.
ANNALS OF HEMATOLOGY (2011)
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib
Annette J. Vangsted et al.
ANNALS OF HEMATOLOGY (2011)
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
Maria T. Di Martino et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens
Juan Du et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma
David C. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Genetic variation associated with bortezomib-induced peripheral neuropathy
Reyna Favis et al.
PHARMACOGENETICS AND GENOMICS (2011)
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
Gabriele Buda et al.
ANNALS OF HEMATOLOGY (2010)
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Antonio Palumbo et al.
BLOOD (2010)
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
Annette J. Vangsted et al.
BMC CANCER (2010)
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
C. Dumontet et al.
BONE MARROW TRANSPLANTATION (2010)
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*
Annette J. Vangsted et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment
Cristina Rodriguez-Antona et al.
HUMAN GENETICS (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Annemiek Broyl et al.
LANCET ONCOLOGY (2010)
Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone
Juan Du et al.
LEUKEMIA RESEARCH (2010)
The IL-1 family: regulators of immunity
John E. Sims et al.
NATURE REVIEWS IMMUNOLOGY (2010)
MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma
Gabriele Buda et al.
ACTA HAEMATOLOGICA (2009)
Association of a single nucleotide polymorphic variation in the human chromosome 19q13.3 with drug responses in the NCI60 cell lines
Kari K. Nissen et al.
ANTI-CANCER DRUGS (2009)
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
Masood A. Shammas et al.
BLOOD (2009)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT
A. J. Vangsted et al.
BONE MARROW TRANSPLANTATION (2009)
A polymorphism in NFKB1 is associated with improved effect of interferon-alpha maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support
Annette J. Vangsted et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Enforced Expression of PPP1R13L Increases Tumorigenesis and Invasion Through p53-Dependent and p53-Independent Mechanisms
Magdalena J. Laska et al.
MOLECULAR CARCINOGENESIS (2009)
ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma
Stephen Drain et al.
LEUKEMIA & LYMPHOMA (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Bisphosphonate-related osteonecrosis: genetic and acquired risk factors
M. E. Sarasquete et al.
ORAL DISEASES (2009)
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
First thalidomide clinical trial in multiple myeloma: a decade later
Frits van Rhee et al.
BLOOD (2008)
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450CYP2C8 in multiple myeloma:: a genome-wide single nucleotide polymorphism analysis
Maria E. Sarasquete et al.
BLOOD (2008)
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
David C. Johnson et al.
BLOOD (2008)
Intracellular signals of T cell costimulation
Jianxun Song et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2008)
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Shu-Feng Zhou et al.
CURRENT DRUG METABOLISM (2008)
Infectious complications after chemotherapy and stem cell transplantation in multiple myeloma: Implications of Fc gamma receptor and myeloperoxidase promoter polymorphisms
Ingolf Molle et al.
LEUKEMIA & LYMPHOMA (2008)
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms
Valentina Maggini et al.
LEUKEMIA RESEARCH (2008)
MDR1 diplotypes as prognostic markers in multiple myeloma
Valentina Maggini et al.
PHARMACOGENETICS AND GENOMICS (2008)
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
S. -F. Zhou
XENOBIOTICA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
Ulf-Henrik Mellqvist et al.
CANCER (2008)
Non-conventional signal transduction by type I interferons:: The NF-κB pathway
Ziyun Du et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma
Yonghua Li et al.
HAEMATOLOGICA (2007)
Expression of the RAI gene is conducive to apoptosis:: Studies of induction and interference
Magdalena J. Laska et al.
EXPERIMENTAL CELL RESEARCH (2007)
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Pieter Sonneveld et al.
HAEMATOLOGICA (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MDR1 polymorphism influences the outcome of multiple myeloma patients
Gabriele Buda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Patterns of survival in multiple myeloma:: A population-based study of patients diagnosed in Sweden from 1973 to 2003
Sigurdur Yngvi Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation
Annette Vangsted et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma
Celine Schilthuizen et al.
HAEMATOLOGICA (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation
V. Maggini et al.
LEUKEMIA (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
J. Rosemary et al.
CURRENT CLINICAL PHARMACOLOGY (2007)
MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells
Noha N. Salama et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
I. Molle et al.
BONE MARROW TRANSPLANTATION (2006)
Impact of age on survival after intensive therapy for multiple myeloma:: a population-based study by the Nordic Myeloma Study Group
S Lenhoff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context
HM Chen et al.
HUMAN MOLECULAR GENETICS (2006)
Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1
YN Xiong et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2006)
The P2X7 receptor gene polymorphism 1513 A→C has no effect on clinical prognostic markers and survival in multiple myeloma
S Paneesha et al.
LEUKEMIA & LYMPHOMA (2006)
Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib
V Uttamsingh et al.
DRUG METABOLISM AND DISPOSITION (2005)
Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites
T Pekol et al.
DRUG METABOLISM AND DISPOSITION (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P4502C19
R Timm et al.
PHARMACOGENOMICS JOURNAL (2005)
Clinical pharmacokinetics of cyclophosphamide
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer
U Vogel et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2004)
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
RK Dasgupta et al.
BLOOD (2003)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities
N Morita et al.
BIOCHEMICAL PHARMACOLOGY (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55
BA Nexo et al.
CARCINOGENESIS (2003)
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human
D Bergamaschi et al.
NATURE GENETICS (2003)
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
VJ Spanswick et al.
BLOOD (2002)
Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts
E Rockenbauer et al.
CARCINOGENESIS (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes
YW Qiao et al.
CARCINOGENESIS (2002)
PPARγ:: a nuclear regulator of metabolism, differentiation, and cell growth
ED Rosen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
In vitro evidence for homologous recombinational repair in resistance to melphalan
ZM Wang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced in multiple myeloma
Q Chen et al.
BLOOD (2001)
Repair of DNA interstrand cross-links
MLG Dronkert et al.
MUTATION RESEARCH-DNA REPAIR (2001)
XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects
G Matullo et al.
CARCINOGENESIS (2001)
Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
JA Keifer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment
FE Davies et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Nucleotide excision repair and human syndromes
J de Boer et al.
CARCINOGENESIS (2000)
分享论文
